Envoy Medical Cash & Equivalents Growth & History (COCH)
Envoy Medical's cash and equivalents was $3.7M for fiscal 2025.
View full Envoy Medical company overviewEnvoy Medical annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.7M | −$1.7M | −31.81% |
| 2024 | 2024-12-31 | $5.5M | $1.3M | +29.99% |
| 2023 | 2023-12-31 | $4.2M | $4.0M | +2204.92% |
| 2022 | 2022-12-31 | $183,000 | $33,155 | +22.13% |
| 2021 | 2021-12-31 | $149,845 | — | — |
Envoy Medical quarterly cash and equivalents
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.7M | $14.4M | +272.21% |
| Q1 2026 | 2026-03-31 | $25.3M | $19.9M | +375.36% |
| Q4 2025 | 2025-12-31 | $3.7M | −$1.7M | −31.81% |
| Q3 2025 | 2025-09-30 | $3.6M | −$868,000 | −19.62% |
| Q2 2025 | 2025-06-30 | $5.3M | $3.5M | +202.81% |
| Q1 2025 | 2025-03-31 | $5.3M | $367,000 | +7.42% |
| Q4 2024 | 2024-12-31 | $5.5M | $1.3M | +29.99% |
| Q3 2024 | 2024-09-30 | $4.4M | −$3.0M | −40.54% |
| Q2 2024 | 2024-06-30 | $1.7M | $1.6M | +1215.03% |
| Q1 2024 | 2024-03-31 | $4.9M | $4.8M | +4653.89% |
| Q4 2023 | 2023-12-31 | $4.2M | $4.0M | +2204.92% |
| Q3 2023 | 2023-09-30 | $7.4M | $7.1M | +2363.60% |
| Q2 2023 | 2023-06-30 | $132,773 | −$344,175 | −72.16% |
| Q1 2023 | 2023-03-31 | $104,020 | −$23,085 | −18.16% |
| Q4 2022 | 2022-12-31 | $183,000 | $33,155 | +22.13% |
| Q3 2022 | 2022-09-30 | $301,997 | −$730,018 | −70.74% |
| Q2 2022 | 2022-06-30 | $476,948 | −$1.3M | −72.58% |
| Q1 2022 | 2022-03-31 | $127,105 | −$2.0M | −94.10% |
| Q4 2021 | 2021-12-31 | $149,845 | $124,845 | +499.38% |
| Q3 2021 | 2021-09-30 | $1.0M | — | — |
| Q2 2021 | 2021-06-30 | $1.7M | — | — |
| Q1 2021 | 2021-03-31 | $2.2M | — | — |
| As of Dec 31, 2020 | 2020-12-31 | $25,000 | — | — |
Envoy Medical cash and equivalents trends
Between the periods ended 2021-12-31 and 2025-12-31, Envoy Medical's cash and equivalents increased from $149,845 to $3.7M, a change of $3.6M. The latest reported quarter, Q2 2026, shows $19.7M.
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Envoy Medical source filings ↗